Last reviewed · How we verify
A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer
The purpose of this study is to compare whether a 3-month treatment is at least not inferior to a 6-month treatment (FOLFOX-4 6 vs. 12 cycles or XELOX 4 cycles vs. 8 cycles) in terms of RFS in patients with high risk stage II or stage III radically resected colon cancer.
Details
| Lead sponsor | Hellenic Oncology Research Group |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 2000 |
| Start date | 2010-10 |
| Completion | 2017-12 |
Conditions
- CRC
Interventions
- 5-Fluorouracil
- Leucovorin
- Oxaliplatin
- Capecitabine
- Oxaliplatin
- 5-Fluorouracil
- Leucovorin
- Capecitabine
- Oxaliplatin
- Oxaliplatin
Primary outcomes
- Relapse Free Survival — 3-years
Countries
Greece